Compounding Chemotherapy Industry Anticipated to Expand at 6.1% CAGR During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Compounding Chemotherapy Market Between 2025 And 2029?

The compounding chemotherapy market size has experienced significant expansion in recent years. It is anticipated to expand from $5.74 billion in 2024 to $6.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.3%. The market’s historic growth stemmed from factors such as increasing cancer incidence, growing adoption of hospital pharmacies, rising use of antineoplastic agents, an increasing focus on patient-specific dosing, and the expanding role of oncology specialty clinics.

The compounding chemotherapy market size is anticipated to experience robust expansion in the coming years. By 2029, this market is projected to reach $7.74 billion, expanding at a compound annual growth rate (CAGR) of 6.1%. Several factors will drive this growth during the forecast period, including an increased focus on precision medicine, a surge in the need for oral and injectable chemotherapy compounds, a greater adoption of hormonal and biologic agents in cancer treatment, a stronger push to minimize drug waste, and an escalated requirement for targeted cancer treatments. Key trends expected over the forecast period encompass the embrace of technology in automated compounding devices, the creation of customized chemotherapy dosing regimens, the development of mobile applications to aid chemotherapy workflows, the merging of electronic health records (EHRs) with compounding systems, and the incorporation of barcode verification into compounding procedures.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp

Which Major Market Drivers Are Shaping The Future Of The Compounding Chemotherapy Market?

The rising incidence of cancer cases is anticipated to spur the expansion of the compounding chemotherapy market moving forward. Cancer is defined as a collection of diseases marked by the unchecked proliferation and dissemination of abnormal cells within the body. The escalating occurrence of cancer is primarily attributable to unhealthy habits, including poor dietary choices, insufficient physical activity, tobacco use, excessive alcohol consumption, and prolonged exposure to environmental contaminants, all of which significantly elevate the likelihood of developing various cancer types. Compounding chemotherapy supports cancer treatment by facilitating custom medication formulations tailored to individual patient requirements, thereby enhancing effectiveness and reducing adverse reactions. For example, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2022, Australia diagnosed 160,570 cancer cases, representing an increase of 3,789 cases from 156,781 in 2021. Consequently, the growing prevalence of cancer cases acts as a key driver for the compounding chemotherapy market’s development.

What Are The Key Segments In The Compounding Chemotherapy Market?

The compounding chemotherapy market covered in this report is segmented –

1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs

2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal

3) By Technology: With Robotic Arms, Without Robotic Arms

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings

Subsegments:

1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors

2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists

3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators

4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors

5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs

What Long-Term Trends Will Shape The Future Growth Of The Compounding Chemotherapy Industry?

Leading companies in the compounding chemotherapy market are increasingly focusing on developing innovative solutions, such as robotic chemotherapy automation systems, to improve the accuracy, safety, and efficiency of personalized cancer treatment preparation. Robotic chemotherapy automation systems are advanced machines specifically designed to precisely and safely prepare customized chemotherapy doses by automating the compounding process, thereby reducing both human error and contamination risks. For instance, in February 2024, Simplivia Healthcare Ltd., a healthcare technology company based in Israel, launched its Smart Compounders Advanced Systems to automate and streamline the preparation of cytotoxic (chemotherapy) drugs. These systems are capable of handling the compounding of cytostatics and antibodies with a capacity ranging from 20 to 40 preparations per hour, incorporating automatic gravimetric verification and comprehensive documentation to ensure high levels of accuracy. They significantly minimize pharmacy staff’s exposure to hazardous substances and are engineered for effortless integration into existing laminar airflow (LAF) cabinets or isolators without requiring any modifications.

Who Are The Primary Competitors In The Global Compounding Chemotherapy Market?

Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Option Care Health Inc., ICU Medical Inc., Dedalus S.p.A., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, Stokes Healthcare Inc, McGuff Compounding Pharmacy Services Inc., Accord Healthcare Limited, Epicur Pharma LLC, Simplivia Healthcare Ltd., AmerisourceBergen Corporation, Kapsam Health Products Ltd., PharMEDium Services LLC.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Compounding Chemotherapy Market?

North America was the largest region in the compounding chemotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Compounding Chemotherapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25724&type=smp

Browse Through More Reports Similar to the Global Compounding Chemotherapy Market 2025, By The Business Research Company

Chemotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Oncology Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795